VISTAGEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 2.12K shares.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 211.00 shares.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2026 was 2.33K shares.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares, a 100.00% decline from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 9.53K shares, a 19.71% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-14 | 2.33K shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | 2.33K shares 10-K · filed 2026-06-15 |
| 2025-12-31 | 2.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | 2.33K shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | 211.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | 211.00 shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-14 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-17 | 0.00 shares 10-K · filed 2025-06-17 |
| 2024-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | 0.00 shares derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | 0.00 shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 0.00 shares 10-Q · filed 2025-08-07 | 0.00 shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-11 | 0.00 shares 10-K · filed 2024-06-11 |
| 2023-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | |
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-13 | |
| 2023-03-31 | 9.53K shares 10-K · filed 2023-06-28 | |
| 2022-03-31 | 11.87K shares 10-K · filed 2023-06-28 | |
| 2021-03-31 | 355.00K shares 10-K · filed 2022-06-23 | |
| 2020-03-31 | 0.00 shares 10-K · filed 2021-06-29 | |
| 2019-03-31 | 29.25K shares 10-K · filed 2020-06-29 | |
| 2018-03-31 | 0.00 shares 10-K · filed 2019-06-25 | |
| 2017-03-31 | 0.00 shares 10-K · filed 2018-06-26 | |
| 2016-03-31 | 0.00 shares 10-K · filed 2017-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |